Medical Devices US

US Cancer Genomic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US Cancer Genomic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.75 Bn Placeholder estimate
Estimate 2025 $6.34 Bn 42.1% of the global market
Projected 2034 $15.20 Bn 139.7% Adds $8.86 Bn over 9 forecast years
CAGR 2025–2034 10.2% Faster than 79% of 173 Medical Devices markets here
Key players 6 +1
  • US is 42.13% of the global market.
  • In North America, the largest is US (this report) at $6.34 Bn.
  • Fastest growing: Canada at 12% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$8.86 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Genomic Testing Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.75 Bn — —
2025 (base) $6.34 Bn +$587.0 Mn —
2026 (forecast) $6.99 Bn +$646.9 Mn +10.2%
2027 (forecast) $7.70 Bn +$712.9 Mn +21.4%
2028 (forecast) $8.49 Bn +$785.6 Mn +33.8%
2029 (forecast) $9.35 Bn +$865.7 Mn +47.5%
2030 (forecast) $10.31 Bn +$954.0 Mn +62.5%
2031 (forecast) $11.36 Bn +$1.05 Bn +79.1%
2032 (forecast) $12.52 Bn +$1.16 Bn +97.4%
2033 (forecast) $13.79 Bn +$1.28 Bn +117.5%
2034 (forecast) $15.20 Bn +$1.41 Bn +139.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US Cancer Genomic Testing Market Analysis at a glance
Market size, 2025$6.34 Bn placeholder estimate
Forecast, 2034$15.20 Bn placeholder estimate
Growth (CAGR), 2025–203410.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, sample and end user (see all)
Key playersRoche, Myriad Genetics, Inc., Illumina, Inc., Guardant Health, Inc., Caris Life Sciences and 1 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US Cancer Genomic Testing Market Analysis Executive Summary

Cancer genomic tests read the DNA of tumours or blood to find mutations that guide treatment or show inherited cancer risk.

Key segments of the cancer Genomic Testing market include test (Comprehensive Genomic Profiling, Hereditary Cancer Panels and Single-Gene Tests) and sample (Tissue, Blood and Saliva).

Bar chart: US Cancer Genomic Testing market size, 2024–2034, placeholder estimates. $5.75 Bn in 2024, $6.34 Bn in 2025 and $15.20 Bn in 2034, 10.2% CAGR.
US Cancer Genomic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US Cancer Genomic Testing Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Genomic Testing market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Genomic Testing market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Genomic Testing market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Genomic Testing Market in US

The cancer Genomic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Genomic Testing Market in US

Cancer Genomic Testing in the US: rules and payment

The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how cancer Genomic Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Genomic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Genomic Testing in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Genomic Testing market in the US?
Placeholder estimate: about $6.34 Bn in 2025, rising to about $15.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Genomic Testing market in the US growing?
Placeholder estimate: about 10.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Genomic Testing market report cover?
The report splits the market by test (Comprehensive Genomic Profiling, Hereditary Cancer Panels, Single-Gene Tests), sample (Tissue, Blood, Saliva) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Cancer Genomic Testing market?
Key players include Roche, Myriad Genetics, Inc., Illumina, Inc., Guardant Health, Inc., Caris Life Sciences and NeoGenomics Laboratories.
What is driving the Cancer Genomic Testing market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Genomic Testing market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Genomic Testing in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How much research is published on Cancer Genomic Testing?
PubMed lists 24 papers on Cancer Genomic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in US

See all

Related on oncology and genomics

See the topic